China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

Researchers from Newcastle University, and colleagues from Spain, Canada and Egypt, have successfully trialled two new qPCR assays to help detect the presence of transmissible AMR using water and wastewater samples.

GenomSys said Wednesday that it has received CE marking for the GenomSys Variant Analyzer.

Autobio Diagnostics Co., Ltd (603658.SH) released the third quarter report：the first three quarters of this year's total sale is CNY 2.695 billion, up 31.64% year on year. Net profit attributable to shareholders of listed companies reached was CNY 717 million, up 39.33% year-on-year.

The US Food and Drug Administration last week granted Emergency Use Authorization for InBios International's SCoV-2 Detect Neutralizing Ab ELISA immunoassay for SARS-CoV-2.

People at risk from strokes and heart attacks could benefit from personalised clotting profiles to help clinicians prescribe more precise treatments, thanks to new research.

As a leading company of immunoassay solutions, YHLO’s core products have gained recognition from professionals in the field. Top Chinese hospitals including Fuwai Hospital, Peking Union Medical College Hospital (PUMCH), Beijing Hospital and more have been cooperating with YHLO for years.

Amazon Care will be rolled out in additional cities in 2021, including Dallas, Chicago, Philadelphia, Boston and Los Angeles "just to name a few," Kristen Helton, the director of Amazon Care, said at the annual HLTH conference on Tuesday.

Genetron Health said Friday that it has entered into an exclusive agreement with Jiangsu Fosun Pharmaceutical Sales, a subsidiary of Shanghai Fosun Pharmaceutical, to commercialize its minimal residual disease assay Seq-MRD.

Armed with a novel strategy they developed for bolstering the body’s immune response, scientists at Albert Einstein College of Medicine have successfully suppressed HIV infections in mice—offering a path to a functional cure for HIV and other chronic viral infections.

Total sales growth of 10.7% to $23.3 Billion with operational growth of 9.9%* and adjusted operational growth of 10.6%. Earnings per share of $1.37 increasing 3.0% and adjusted earnings per share of $2.60 increasing 18.2%.